- Previous Close
126.88 - Open
125.95 - Bid 90.57 x 200
- Ask 124.71 x 100
- Day's Range
121.83 - 126.48 - 52 Week Range
76.53 - 131.49 - Volume
428,702 - Avg. Volume
816,322 - Market Cap (intraday)
29.828B - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-2.02 - Earnings Date Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 2, 2022
- 1y Target Est
135.58
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
www.biontech.deRecent News: BNTX
View MorePerformance Overview: BNTX
Trailing total returns as of 1/8/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNTX
View MoreValuation Measures
Market Cap
30.42B
Enterprise Value
13.32B
Trailing P/E
166.87
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.69
Price/Book (mrq)
1.53
Enterprise Value/Revenue
4.22
Enterprise Value/EBITDA
110.81
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.36%
Return on Assets (ttm)
-1.24%
Return on Equity (ttm)
-2.40%
Revenue (ttm)
3.04B
Net Income Avi to Common (ttm)
-466.9M
Diluted EPS (ttm)
-2.02
Balance Sheet and Cash Flow
Total Cash (mrq)
16.71B
Total Debt/Equity (mrq)
1.27%
Levered Free Cash Flow (ttm)
1.41B